Roche to buy diabetes app provider mySugr

Print Friendly, PDF & Email

BASEL, Switzerland — Roche has entered an agreement to acquire mySugr GmbH, a Vienna-based provider of diabetes management apps and services.

The drug maker said mySugr’s leading mobile diabetes platform, with more than 1 million users globally, will become a linchpin of its new patient-centered digital health services platform in diabetes care.

mySugr appFounded in 2012 and operating a U.S. office in San Diego, mySugr offers apps and services that link diabetes coaching, therapy management, unlimited test strips, automated data tracking and seamless integration with medical devices to ease the daily chore of living with diabetes. The mySugr App is available in 52 countries and 13 languages.

The Roche Diabetes Care unit includes the Accu-Chek brand, whose offerings include blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs.

“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” stated Roland Diggelmann, chief executive officer of Roche Diagnostics. “Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”

Financial terms of the transaction weren’t disclosed. MySugr is expected to remain a separate legal entity with an open platform for all diabetes devices and services, Roche said.

Users will continue to have the ability to automatically upload blood glucose data from their preferred device into the mySugr logbook app, as well as facilitated data sharing with health professionals and caregivers.

“We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” commented Frank Westermann, CEO and co-founder of mySugr. “The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”



Comments are closed.